281 related articles for article (PubMed ID: 28470676)
1. Acetyl-coenzyme A carboxylase inhibition reduces de novo lipogenesis in overweight male subjects: A randomized, double-blind, crossover study.
Stiede K; Miao W; Blanchette HS; Beysen C; Harriman G; Harwood HJ; Kelley H; Kapeller R; Schmalbach T; Westlin WF
Hepatology; 2017 Aug; 66(2):324-334. PubMed ID: 28470676
[TBL] [Abstract][Full Text] [Related]
2. Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis.
Lawitz EJ; Coste A; Poordad F; Alkhouri N; Loo N; McColgan BJ; Tarrant JM; Nguyen T; Han L; Chung C; Ray AS; McHutchison JG; Subramanian GM; Myers RP; Middleton MS; Sirlin C; Loomba R; Nyangau E; Fitch M; Li K; Hellerstein M
Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1983-1991.e3. PubMed ID: 29705265
[TBL] [Abstract][Full Text] [Related]
3. Dose-dependent quantitative effects of acute fructose administration on hepatic de novo lipogenesis in healthy humans.
Beysen C; Ruddy M; Stoch A; Mixson L; Rosko K; Riiff T; Turner SM; Hellerstein MK; Murphy EJ
Am J Physiol Endocrinol Metab; 2018 Jul; 315(1):E126-E132. PubMed ID: 29558206
[TBL] [Abstract][Full Text] [Related]
4. Elevated de novo lipogenesis, slow liver triglyceride turnover, and clinical correlations in nonalcoholic steatohepatitis patients.
Lawitz EJ; Li KW; Nyangau E; Field TJ; Chuang JC; Billin A; Wang L; Wang Y; Huss RS; Chung C; Subramanian GM; Myers RP; Hellerstein MK
J Lipid Res; 2022 Sep; 63(9):100250. PubMed ID: 35835205
[TBL] [Abstract][Full Text] [Related]
5. Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems.
Ross TT; Crowley C; Kelly KL; Rinaldi A; Beebe DA; Lech MP; Martinez RV; Carvajal-Gonzalez S; Boucher M; Hirenallur-Shanthappa D; Morin J; Opsahl AC; Vargas SR; Bence KK; Pfefferkorn JA; Esler WP
Cell Mol Gastroenterol Hepatol; 2020; 10(4):829-851. PubMed ID: 32526482
[TBL] [Abstract][Full Text] [Related]
6. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Liver-Targeting Acetyl-CoA Carboxylase Inhibitor (PF-05221304): A Three-Part Randomized Phase 1 Study.
Bergman A; Carvajal-Gonzalez S; Tarabar S; Saxena AR; Esler WP; Amin NB
Clin Pharmacol Drug Dev; 2020 May; 9(4):514-526. PubMed ID: 32065514
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non-alcoholic fatty liver disease: Results from two early-phase randomized trials.
Beysen C; Schroeder P; Wu E; Brevard J; Ribadeneira M; Lu W; Dole K; O'Reilly T; Morrow L; Hompesch M; Hellerstein MK; Li K; Johansson L; Kelly PF
Diabetes Obes Metab; 2021 Mar; 23(3):700-710. PubMed ID: 33289350
[TBL] [Abstract][Full Text] [Related]
8. Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation.
Bates J; Vijayakumar A; Ghoshal S; Marchand B; Yi S; Kornyeyev D; Zagorska A; Hollenback D; Walker K; Liu K; Pendem S; Newstrom D; Brockett R; Mikaelian I; Kusam S; Ramirez R; Lopez D; Li L; Fuchs BC; Breckenridge DG
J Hepatol; 2020 Oct; 73(4):896-905. PubMed ID: 32376414
[TBL] [Abstract][Full Text] [Related]
9. Selective Acetyl-CoA Carboxylase 1 Inhibitor Improves Hepatic Steatosis and Hepatic Fibrosis in a Preclinical Nonalcoholic Steatohepatitis Model.
Tamura YO; Sugama J; Iwasaki S; Sasaki M; Yasuno H; Aoyama K; Watanabe M; Erion DM; Yashiro H
J Pharmacol Exp Ther; 2021 Nov; 379(3):280-289. PubMed ID: 34535562
[TBL] [Abstract][Full Text] [Related]
10. Fatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities.
Syed-Abdul MM; Parks EJ; Gaballah AH; Bingham K; Hammoud GM; Kemble G; Buckley D; McCulloch W; Manrique-Acevedo C
Hepatology; 2020 Jul; 72(1):103-118. PubMed ID: 31630414
[TBL] [Abstract][Full Text] [Related]
11. Acetyl-CoA Carboxylase Inhibition Reverses NAFLD and Hepatic Insulin Resistance but Promotes Hypertriglyceridemia in Rodents.
Goedeke L; Bates J; Vatner DF; Perry RJ; Wang T; Ramirez R; Li L; Ellis MW; Zhang D; Wong KE; Beysen C; Cline GW; Ray AS; Shulman GI
Hepatology; 2018 Dec; 68(6):2197-2211. PubMed ID: 29790582
[TBL] [Abstract][Full Text] [Related]
12. Human sebum requires de novo lipogenesis, which is increased in acne vulgaris and suppressed by acetyl-CoA carboxylase inhibition.
Esler WP; Tesz GJ; Hellerstein MK; Beysen C; Sivamani R; Turner SM; Watkins SM; Amor PA; Carvajal-Gonzalez S; Geoly FJ; Biddle KE; Purkal JJ; Fitch M; Buckeridge C; Silvia AM; Griffith DA; Gorgoglione M; Hassoun L; Bosanac SS; Vera NB; Rolph TP; Pfefferkorn JA; Sonnenberg GE
Sci Transl Med; 2019 May; 11(492):. PubMed ID: 31092695
[TBL] [Abstract][Full Text] [Related]
13. Hepatic de novo lipogenesis is present in liver-specific ACC1-deficient mice.
Harada N; Oda Z; Hara Y; Fujinami K; Okawa M; Ohbuchi K; Yonemoto M; Ikeda Y; Ohwaki K; Aragane K; Tamai Y; Kusunoki J
Mol Cell Biol; 2007 Mar; 27(5):1881-8. PubMed ID: 17210641
[TBL] [Abstract][Full Text] [Related]
14. Acetyl-CoA carboxylase 1 and 2 inhibition ameliorates steatosis and hepatic fibrosis in a MC4R knockout murine model of nonalcoholic steatohepatitis.
Matsumoto M; Yashiro H; Ogino H; Aoyama K; Nambu T; Nakamura S; Nishida M; Wang X; Erion DM; Kaneko M
PLoS One; 2020; 15(1):e0228212. PubMed ID: 31990961
[TBL] [Abstract][Full Text] [Related]
15. Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease.
Smith GI; Shankaran M; Yoshino M; Schweitzer GG; Chondronikola M; Beals JW; Okunade AL; Patterson BW; Nyangau E; Field T; Sirlin CB; Talukdar S; Hellerstein MK; Klein S
J Clin Invest; 2020 Mar; 130(3):1453-1460. PubMed ID: 31805015
[TBL] [Abstract][Full Text] [Related]
16. GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease.
Loomba R; Kayali Z; Noureddin M; Ruane P; Lawitz EJ; Bennett M; Wang L; Harting E; Tarrant JM; McColgan BJ; Chung C; Ray AS; Subramanian GM; Myers RP; Middleton MS; Lai M; Charlton M; Harrison SA
Gastroenterology; 2018 Nov; 155(5):1463-1473.e6. PubMed ID: 30059671
[TBL] [Abstract][Full Text] [Related]
17. Association between Nicotinamide Phosphoribosyltransferase and de novo Lipogenesis in Nonalcoholic Fatty Liver Disease.
Amirkalali B; Sohrabi MR; Esrafily A; Jalali M; Gholami A; Hosseinzadeh P; Keyvani H; Shidfar F; Zamani F
Med Princ Pract; 2017; 26(3):251-257. PubMed ID: 28092906
[TBL] [Abstract][Full Text] [Related]
18. Acetyl-CoA carboxylase inhibitors in non-alcoholic steatohepatitis: Is there a benefit?
Neokosmidis G; Cholongitas E; Tziomalos K
World J Gastroenterol; 2021 Oct; 27(39):6522-6526. PubMed ID: 34754150
[TBL] [Abstract][Full Text] [Related]
19. Investigating dual inhibition of ACC and CD36 for the treatment of nonalcoholic fatty liver disease in mice.
Devereux CJ; Bayliss J; Keenan SN; Montgomery MK; Watt MJ
Am J Physiol Endocrinol Metab; 2023 Feb; 324(2):E187-E198. PubMed ID: 36629823
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Acetyl-CoA Carboxylase by Phosphorylation or the Inhibitor ND-654 Suppresses Lipogenesis and Hepatocellular Carcinoma.
Lally JSV; Ghoshal S; DePeralta DK; Moaven O; Wei L; Masia R; Erstad DJ; Fujiwara N; Leong V; Houde VP; Anagnostopoulos AE; Wang A; Broadfield LA; Ford RJ; Foster RA; Bates J; Sun H; Wang T; Liu H; Ray AS; Saha AK; Greenwood J; Bhat S; Harriman G; Miao W; Rocnik JL; Westlin WF; Muti P; Tsakiridis T; Harwood HJ; Kapeller R; Hoshida Y; Tanabe KK; Steinberg GR; Fuchs BC
Cell Metab; 2019 Jan; 29(1):174-182.e5. PubMed ID: 30244972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]